文献速递肝肾功能剂量调整特殊人群用药药物相互作用

Claudin 18.2 抗体 Zolbetuximab 的临床药理学特征

Clinical Pharmacology Profile of the Claudin 18.2 Antibody Zolbetuximab.
PubMed 文献 · Clin Pharmacokinet · 2025-08-13

本文综述了靶向 CLDN18.2 的嵌合单克隆抗体 Zolbetuximab 的临床药理学。基于 8 项临床研究(n=714)的群体药代动力学分析显示,其 PK 符合二室模型伴线性及时间依赖性清除;胃切除术可使其 Ctrough 升高≥50% 但无显著获益-风险影响,轻中度肾损伤或轻度肝损伤无需调整剂量,不同种族间 PK 无差异。暴露-反应分析提示较高暴露可能延长生存但增加胃肠道事件及输注相关反应概率。

要点

  • 胃切除术预测使 Zolbetuximab Ctrough 升高≥50%,但未明显影响获益-风险特征。
  • 轻中度肾损伤或轻度肝损伤无需调整剂量。
  • 不同种族(白人、亚洲人、中国人、日本人、韩国人)间 PK 无差异。

核心结论

  • Zolbetuximab 是首个且唯一获批靶向 CLDN18.2 的疗法,为 CLDN18.2 阳性局部晚期不可切除或转移性胃/胃食管结合部癌患者提供新选择。

研究设计与样本

  • 综述,基于 8 项临床研究(n=714)的群体药代动力学分析及暴露-反应分析。

主要发现

  • 静脉给药后 PK 符合二室模型,含线性和时间依赖性清除成分。
  • 基于 800/600 mg/m2 每 3 周方案的模拟,胃切除术(对比无胃切除术)预测使 Ctrough 升高≥50%,但未明显影响获益-风险特征。
  • 轻中度肾损伤或轻度肝损伤无需调整剂量。
  • 不同种族(白人、亚洲人、中国人、日本人、韩国人)间 PK 无差异。
  • 与奥沙利铂或 5-氟尿嘧啶合用未见明显安全性或 PK 影响;抗药抗体发生率低且无临床后果。

关键数值与推荐

  • 800/600 mg/m2 每 3 周方案来自 3 期试验。
  • 胃切除术预测使 Ctrough 升高≥50%。
  • 暴露-反应分析提示较高暴露可能延长生存但增加胃肠道事件及输注相关反应概率。
  • proposed 800/400 mg/m2 每 2 周方案与每 2 周化疗联用,安全性和有效性 comparable 于 800/600 mg/m2 每 3 周方案。

临床怎么用

  • 轻中度肾损伤或轻度肝损伤患者无需调整剂量。
  • 不同种族患者无需调整剂量。
  • 与奥沙利铂或 5-氟尿嘧啶联用无需担心 PK 或安全性相互作用。
  • 胃切除术后患者 Ctrough 升高但无需调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Zolbetuximab is a first-in-class chimeric (mouse/human) monoclonal antibody targeted to the tight junction protein claudin 18.2 (CLDN18.2), an emerging biomarker in gastric/gastroesophageal junction (G/GEJ) cancer. This review summarizes the clinical pharmacology of zolbetuximab on the basis of available clinical trial data. Population pharmacokinetics (PK) were evaluated using data from eight clinical studies (n = 714). Zolbetuximab PK following intravenous administration was described by a two-compartment model with linear and time-dependent clearance components. On the basis of simulations using the 800/600 mg/m2 every 3 weeks (Q3W) dosing regimen from phase 3 trials, gastrectomy (versus no gastrectomy) was predicted to increase zolbetuximab Ctrough by ≥ 50%, but without apparent effects on the benefit-risk profile of zolbetuximab. No dose adjustments are necessary for individuals with mild/moderate renal impairment or mild hepatic impairment. Zolbetuximab PK was not different among the ethnicities evaluated (White, Asian, Chinese, Japanese, Korean). There were no apparent safety or PK ramifications of zolbetuximab coadministration with oxaliplatin or 5-fluorouracil. The incidence of antidrug antibodies to zolbetuximab was low, with no apparent clinical consequence. Exposure-response analysis suggested that higher zolbetuximab exposures may prolong survival outcomes but may also increase the probability of experiencing gastrointestinal events and infusion-related reactions. A proposed alternative 800/400 mg/m2 every 2 weeks (Q2W) regimen for use in combination with Q2W chemotherapy was shown to have comparable safety and efficacy to the 800/600 mg/m2 Q3W regimen. Zolbetuximab, the first and only approved therapy targeted to CLDN18.2, is a valuable new treatment option for patients with CLDN18.2-positive, locally advanced unresectable or metastatic G/GEJ cancer.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Yang J, Yamada A, Shitara K, et al. Clinical Pharmacology Profile of the Claudin 18.2 Antibody Zolbetuximab. Clin Pharmacokinet. 2025. PMID: 40804604. doi:10.1007/s40262-025-01552-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。